Clinical trials
for patients
Learn about available clinical trials
-
November 24, 2025Pamplona/MadridIn recruitment
NOVOFFOX Trial of tumor treatment fields (TTFields, 150 kHz) concomitant with modFOLFIRINOX for the first-line treatment of metastatic pancreatic adenocarcinoma (NOVOFFOX).
The aim of this study is to evaluate the efficacy and safety of TTFields in combination with the chemotherapy you will receive for your cancer (oxaliplatin-irinotecan-fluorouracil, FOLFIRINOX). -
November 19, 2025Pamplona/MadridIn recruitment
PRO001 Clinical trial to evaluate the efficacy and safety of PKB171 intravaginal and postcoital gel in couples with mild male infertility factors.
The primary objective is to verify efficacy (clinical pregnancy defined as intrauterine pregnancy with confirmed heartbeat between weeks 6 and 8 of gestation) up to three treatment cycles with PKB171 gel compared to a placebo vaginal gel in couples with mild male factor infertility. -
November 19, 2025Pamplona/MadridIn recruitment
M22-132 Ensayo de Epcoritamab en combinación con antineoplásicos en pacientes con linfoma no Hodgkin
The purpose of this study is to evaluate a drug called Epcoritamab in combination with other drugs used to treat non-Hodgkin lymphoma (NHL). Epcoritamab may work better when combined with other drugs that treat cancer in different ways. -
November 19, 2025Pamplona/MadridIn recruitment
MK-2870-004 Randomized, open-label, phase 3 clinical trial of MK-2870 in previously treated non-small cell lung cancer with EGFR mutations or other genomic alterations.
El objetivo principal de este estuido es comparar MK-2870 con la quimioterapia con respecto a la SLP según RECIST 1.1 evaluada por evaluada por BICR en CPNM con mutaciones del EGFR mutaciones. -
November 19, 2025Pamplona/MadridIn recruitment
-
November 18, 2025PamplonaIn recruitmentEarly phase
FS222-19101 Trial to evaluate the safety and antitumor activity of FS222, a bispecific antibody against CD137/PD-L1, in subjects with advanced malignant neoplasms
The objective is to determine whether FS222 is safe in the treatment of cancer and the extent to which a person tolerates side effects. -
November 7, 2025Pamplona/MadridIn recruitmentEarly phase
GS-US-570-6015 A Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of GS-1811, an Afucosylated Anti-CCR8 Monoclonal Antibody, as Monotherapy and in Combination With an Anti¿PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors
The objective or purpose of this clinical trial is to test an experimental drug called GS-1811 alone, GS-1811 in combination with zimberelimab (also known as AB122 or GS-0122), and zimberelimab alone for the treatment of different types of cancer. -
November 4, 2025PamplonaIn recruitment
-
November 4, 2025Pamplona/MadridIn recruitment
GS-US-626-6216 Clinical trial to evaluate zimberelimab and domvanalimab in combination with chemotherapy versus pembrolizumab with chemotherapy as first-line treatment for patients with metastatic non-small cell lung cancer.
The main goal of this study is to determine whether ZIM alone or in combination with DOM and chemotherapy is safe and effective when given to patients with the type of cancer you have. The first standard treatment approved for metastatic NSCLC without gene alterations is anti-PD-(L)1 immunotherapy, which is a drug that helps the immune system target cancer cells for destruction, combined with or without platinum-based chemotherapy. The study will also attempt to understand how the combination of... -
November 4, 2025PamplonaIn recruitmentEarly phase
TV56286-NDG-20039 Trial of TEV-56286 for the treatment of patients with multiple system atrophy
The purpose of this clinical trial is to determine whether an investigational drug called TEV-56286 (also known as ANLE138b) can stabilize, limit, or slow the worsening of AMS symptoms, and to determine the safety and tolerability of this drug in adults with AMS, compared to placebo.